STRONGBRIDGE BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBBP and Encourages Investors to Contact the Firm
May 24, 2021 12:43 ET
|
Bragar Eagel & Squire
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Xeris Pharmaceuticals Announces a Formulation Development Collaboration with Asahi Kasei Pharma
March 13, 2018 17:00 ET
|
Xeris Pharmaceuticals, Inc.
Chicago, March 13, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development
March 08, 2018 18:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) --
CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...
Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
February 15, 2018 17:00 ET
|
Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.
February 08, 2018 18:30 ET
|
Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of Directors
September 07, 2017 16:30 ET
|
Xeris Pharmaceuticals, Inc.
Chicago, IL and Austin, TX, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for...
Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program
June 16, 2017 07:51 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX, June 16, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) announced today that results from three clinical studies of the company’s investigational...
Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions
June 05, 2017 08:15 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX; , June 05, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) today announced that data from the company’s non-aqueous, room temperature stable, ready to use...
Xeris Pharmaceuticals Announces Closing of $30 Million Financing
May 17, 2017 19:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX, May 17, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations...
Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO
January 09, 2017 07:00 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of...